3',4'-seco-2'-desoxy-α-thymidine | 120019-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3',4'-seco-2'-desoxy-α-thymidine
• 英文别名: 1-[(1S)-3-hydroxy-1-(2-hydroxyethoxy)propyl]-5-methylpyrimidine-2,4-dione
• CAS: 120019-99-0
• 化学式: C₁₀H₁₆N₂O₅
• 分子量: 244.247
• InChiKey: CHQLZIBZRVIBFN-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 3',4'-seco-2'-desoxy-α-thymidine 在 吡啶 作用下， 反应 16.0h， 生成 Acetic acid (S)-3-(2-acetoxy-ethoxy)-3-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-propyl ester
  参考文献：
  名称：

  Synthesis of enantiomers of 3?,4?-seco-2?-desoxythymidine

  摘要：

  DOI：

  10.1007/bf00633175
• 作为产物：
  描述：

  Acetic acid (S)-3-(2-acetoxy-ethoxy)-3-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-propyl ester 在 氨 作用下， 以 甲醇 为溶剂， 生成 3',4'-seco-2'-desoxy-α-thymidine
  参考文献：
  名称：

  Synthesis of enantiomers of 3?,4?-seco-2?-desoxythymidine

  摘要：

  DOI：

  10.1007/bf00633175

文献信息

• Combinatorial protecting group strategy for multifunctional molecules
  申请人：——

  公开号：US20030054410A1

  公开（公告）日：2003-03-20

  In general, the invention features the use of novel protection schemes and solid phase synthesis reactions to generate molecules of core structure M, which have a plurality of moieties, each of which can be individually deprotected or subsequently derivatized. In a preferred process, M is a multifunctional low molecular weight compound, such as a saccharide, aminosugar, deoxysugar, nucleoside, nucleotide, coenzyme, amino acid, lipid, steroid, vitamin, hormone, alkaloid, or small molecule drug. In a particularly preferred process, M is an oligomeric compound (e.g. a oligosaccharide, oligonucleotide, peptide or protein).

  一般而言，本发明采用新颖的保护方案和固相合成反应来生成具有核心结构M的分子，该分子具有多个基团，每个基团可以单独去保护或随后衍生化。在首选的过程中，M是多功能低分子量化合物，例如糖，氨基糖，去氧糖，核苷，核苷酸，辅酶，氨基酸，脂类，类固醇，维生素，激素，生物碱或小分子药物。在特别首选的过程中，M是寡聚化合物（例如寡糖，寡核苷酸，肽或蛋白质）。
• beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20070087995A1

  公开（公告）日：2007-04-19

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗患有乙型肝炎的宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-erythro-戊糖核苷的化学式为：其中R选自H，直链，支链或环烷基，CO-烷基，CO-芳基，CO-烷氧基烷基，CO-芳氧基烷基，CO-取代芳基，烷基磺酰基，芳基磺酰基，芳基烷基磺酰基，氨基酸残基，单磷酸、二磷酸或三磷酸，或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可选择性地被取代。2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-erythro-戊糖核苷或其他抗乙型肝炎药物联合使用。
• Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
  申请人：Gosselin Gilles

  公开号：US20080064655A1

  公开（公告）日：2008-03-13

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-axyl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予一种抗HBV生物活性2'-脱氧-β-L-赤霉糖核苷或其药学上可接受的盐或前药的有效量，其中2'-脱氧-β-L-赤霉糖核苷的化学式为：其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳烷基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单、二或三磷酸盐或磷酸衍生物；BASE是一种嘌呤或嘧啶碱基，可以选择性地被取代。2'-脱氧-β-L-赤霉糖核苷或其药学上可接受的盐或前药可以单独或与另一种2'-脱氧-β-L-赤霉糖核苷或另一种抗乙型肝炎药物联合给予。
• COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES
  申请人：——

  公开号：US20030194741A1

  公开（公告）日：2003-10-16

  In general, the invention features the use of novel protection schemes and solid phase synthesis reactions to generate molecules of core structure M, which have a plurality of functionalities, each of which can be individually protected or functionalized. In a preferred process, M is a multifunctional low molecular weight compound, such as a saccharide, aminosugar, deoxysugar, nucleoside, nucleotide, coenzyme, amino acid, lipid, steroid, vitamin, hormone, alkaloid, or small molecule drug. In a particularly preferred process, M is an oligomeric compound (e.g. a polysaccharide, polynucleotide, peptide or protein).

  一般来说，本发明的特点是利用新颖的保护方案和固相合成反应生成核心结构 M 的分子，这些分子具有多种官能度，其中每种官能度都可以单独保护或官能化。在一种优选工艺中，M 是一种多功能低分子量化合物，如糖、氨基糖、脱氧糖、核苷、核苷酸、辅酶、氨基酸、脂质、类固醇、维生素、激素、生物碱或小分子药物。在一种特别优选的工艺中，M 是一种低聚化合物（如多糖、多核苷酸、肽或蛋白质）。
• MIXAJLOV, S. N.;EFIMTSEVA, E. V., XIMIYA GETEROTSIKL. SOED.,(1988) N 7, 947-951
  作者：MIXAJLOV, S. N.、EFIMTSEVA, E. V.

  DOI：——

  日期：——